Testing effectiveness (Phase 2)Looking for participantsNCT06495515
What this trial is testing
Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer
Who this might be right for
CANCERBRAEST CANCERLate Frontline
Tianjin Medical University Cancer Institute and Hospital 36